Articles in this section

• AFRICAN DECLARATION TO ELIMINATE HEPATITIS C AND IMPROVE THE HEALTH OF PEOPLE WHO USE DRUGS Cape Town, South Africa, 20 February 2020

  

  If your organization would like to sign on, please contact INHSU: info@inhsuafrica2020.com
  We, the community of people working to eliminate hepatitis C in the African region express alarm regarding the increasing impact of drug use, hepatitis C, and other viral co-infections (including HIV and (...) More

  21 February 2020

• #FreeChangsha3: Wrongfully Detained HIV/Viral Hepatitis Activists

  

  Three Chinese lawyers and advocates, Cheng Yuan, Wu Gejianxiong, and Liu Yongze, who work on employment discrimination and disability justice for people living with HIV and viral hepatitis, have been wrongfully detained in Hunan, China since 22 July 2019. More

  19 August 2019

• Hepatitis C cure, sofosbuvir, turns 5 years old: The vast majority of people still have not been treated

  

  Advocates scandalized that Gilead’s hepatitis C profits have raked in US$25.8 billion, which could have treated everyone while still earning US$16 billion in profits.
  6 December 2018, Paris, France, New York, NY— People living with hepatitis C, access to medicines activists, and the medical (...) More

  6 December 2018

• APN+ joins MTAAG+ in congratulating Malaysia on sofosbuvir compulsory license CL ends Gilead’s dangerous games with lives of HepC patients in Malaysia Result of hard fought efforts of community-based groups, NGOs and treatment providers

  20 September 2017, Bangkok and Kuala Lumpur: The Asia-Pacific Network of People living with HIV (APN+) joins the Positive Malaysian Treatment Access and Advocacy Group (MTAAG+) in welcoming the approval of a government use license (also known as compulsory license or CL) in Malaysia for (...) More

  6 October 2017

• Hepatitis C: Gilead patent on sofosbuvir partially maintained following MdM patent opposition Paris, October 5th 2016

  

  European Patent Office (EPO) has taken its decision following Doctors of the World - Médecins du Monde (MdM) patent opposition on Gilead Sciences’ Sofosbuvir. MdM applauds EPO’s decision to revoke partially the patent.
  MdM has filled an opposition on the patent granted to Gilead Sciences for (...) More

  5 October 2016